In the last trading session, 2.58 million Denali Therapeutics Inc (NASDAQ:DNLI) shares changed hands as the company’s beta touched 1.51. With the company’s per share price at $11.47 changed hands at -$0.13 or -1.12% during last session, the market valuation stood at $1.67B. DNLI’s last price was a discount, traded about -190.58% off its 52-week high of $33.33. The share price had its 52-week low at $10.57, which suggests the last value was 7.85% up since then. When we look at Denali Therapeutics Inc’s average trading volume, we note the 10-day average is 2.04 million shares, with the 3-month average coming to 1.21 million.
Analysts gave the Denali Therapeutics Inc (DNLI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.16. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended DNLI as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Denali Therapeutics Inc’s EPS for the current quarter is expected to be -0.71.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Instantly DNLI was in red as seen at the end of in last trading. With action -6.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -43.72%, with the 5-day performance at -6.67% in the red. However, in the 30-day time frame, Denali Therapeutics Inc (NASDAQ:DNLI) is -23.28% down. Looking at the short shares, we see there were 10.51 million shares sold at short interest cover period of 8.02 days.
The consensus price target for the stock as assigned by Wall Street analysts is 38.5, meaning bulls need an upside of 70.21% from its current market value. According to analyst projections, DNLI’s forecast low is 32 with 45 as the target high. To hit the forecast high, the stock’s price needs a -292.33% plunge from its current level, while the stock would need to soar -178.99% for it to hit the projected low.
Consensus estimates given by 11 financial analysts project the company’s revenue in the current quarter to hit an average of 3.24M. 11 analysts are of the opinion that Denali Therapeutics Inc’s revenue for the current quarter will be 7.79M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -4.46%. The 2025 estimates are for Denali Therapeutics Inc earnings to decrease by -12.76%, but the outlook for the next 5-year period is at 7.03% per year.
DNLI Dividends
Denali Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.56% of Denali Therapeutics Inc shares while 90.86% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.46%. There are 90.86% institutions holding the Denali Therapeutics Inc stock share, with BAILLIE GIFFORD & CO the top institutional holder. As of 2024-06-30, the company held 8.1523% of the shares, roughly 13.76 million DNLI shares worth $319.59 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8034% or 13.17 million shares worth $305.91 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and SMALLCAP WORLD FUND INC . With 7.97 shares estimated at $91.43 million under it, the former controlled 5.49% of total outstanding shares. On the other hand, SMALLCAP WORLD FUND INC held about 2.62% of the shares, roughly 3.81 shares worth around $43.67 million.
